Anna Marie Mulligan

Summary

Affiliation: St. Michael's Hospital
Country: Canada

Publications

  1. pmc Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers
    Antonis C Antoniou
    Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Worts Causeway, Cambridge CB1 8RN, UK
    Breast Cancer Res 14:R33. 2012
  2. pmc CK8/18 expression, the basal phenotype, and family history in identifying BRCA1-associated breast cancer in the Ontario site of the breast cancer family registry
    Anna Marie Mulligan
    Keenan Research Centre in the Li Ka Shing Knowledge Institute of St Michael s Hospital and the Department of Laboratory Medicine, St Michael s Hospital, Toronto, Ontario, Canada Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
    Cancer 117:1350-9. 2011
  3. ncbi JAG1 expression is associated with a basal phenotype and recurrence in lymph node-negative breast cancer
    Michael Reedijk
    Department of Surgical Oncology, University of Toronto, Toronto, ON, Canada, M5G 2M9
    Breast Cancer Res Treat 111:439-48. 2008
  4. doi Prognostic effect of basal-like breast cancers is time dependent: evidence from tissue microarray studies on a lymph node-negative cohort
    Anna Marie Mulligan
    Department of Laboratory Medicine, St Michael s Hospital, Toronto, Ontario, Canada
    Clin Cancer Res 14:4168-74. 2008
  5. doi Elevated expression of podocalyxin is associated with lymphatic invasion, basal-like phenotype, and clinical outcome in axillary lymph node-negative breast cancer
    Catherine L Forse
    Fred A Litwin Centre for Cancer Genetics, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, 600 University Avenue, Toronto, Ontario, Canada
    Breast Cancer Res Treat 137:709-19. 2013
  6. pmc Tumoral lymphocytic infiltration and expression of the chemokine CXCL10 in breast cancers from the Ontario Familial Breast Cancer Registry
    Anna Marie Mulligan
    Keenan Research Centre, Li Ka Shing Knowledge Institute of St Michael s Hospital, University of Toronto, Ontario, Canada
    Clin Cancer Res 19:336-46. 2013
  7. ncbi Changes in estrogen receptor, progesterone receptor and Her-2/neu status with time: discordance rates between primary and metastatic breast cancer
    Reuben J Broom
    Princess Margaret Hospital, Toronto, Canada
    Anticancer Res 29:1557-62. 2009
  8. doi Cytokeratin 5 and estrogen receptor immunohistochemistry as a useful adjunct in identifying atypical papillary lesions on breast needle core biopsy
    Andrea Grin
    Department of Laboratory Medicine and Pathobiology, University of Toronto, Canada
    Am J Surg Pathol 33:1615-23. 2009
  9. doi Müllerian adenosarcomas with unusual growth patterns: staging issues
    Blaise Alexander Clarke
    Department of Pathology, University Health Network, Toronto, Ontario, Canada
    Int J Gynecol Pathol 30:340-7. 2011
  10. doi Comparison of clinical schemas and morphologic features in predicting Lynch syndrome in mutation-positive patients with endometrial cancer encountered in the context of familial gastrointestinal cancer registries
    Paul Ryan
    Department of Pathology, Mount Sinai Hospital, Toronto, Ontario, Canada
    Cancer 118:681-8. 2012

Collaborators

Detail Information

Publications18

  1. pmc Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers
    Antonis C Antoniou
    Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Worts Causeway, Cambridge CB1 8RN, UK
    Breast Cancer Res 14:R33. 2012
    ..2)...
  2. pmc CK8/18 expression, the basal phenotype, and family history in identifying BRCA1-associated breast cancer in the Ontario site of the breast cancer family registry
    Anna Marie Mulligan
    Keenan Research Centre in the Li Ka Shing Knowledge Institute of St Michael s Hospital and the Department of Laboratory Medicine, St Michael s Hospital, Toronto, Ontario, Canada Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
    Cancer 117:1350-9. 2011
    ....
  3. ncbi JAG1 expression is associated with a basal phenotype and recurrence in lymph node-negative breast cancer
    Michael Reedijk
    Department of Surgical Oncology, University of Toronto, Toronto, ON, Canada, M5G 2M9
    Breast Cancer Res Treat 111:439-48. 2008
    ..As JAG1 is a target of several oncogenic signaling pathways, and is a ligand for Notch, these data provide novel insights into signaling that may contribute to progression of early stage breast cancer...
  4. doi Prognostic effect of basal-like breast cancers is time dependent: evidence from tissue microarray studies on a lymph node-negative cohort
    Anna Marie Mulligan
    Department of Laboratory Medicine, St Michael s Hospital, Toronto, Ontario, Canada
    Clin Cancer Res 14:4168-74. 2008
    ..Subsequent to this validation, we examined outcome in specific subgroups defined using TMA data...
  5. doi Elevated expression of podocalyxin is associated with lymphatic invasion, basal-like phenotype, and clinical outcome in axillary lymph node-negative breast cancer
    Catherine L Forse
    Fred A Litwin Centre for Cancer Genetics, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, 600 University Avenue, Toronto, Ontario, Canada
    Breast Cancer Res Treat 137:709-19. 2013
    ..001). PODXL has the potential to be a useful biomarker for identifying good prognosis patients in characteristically poor prognosis breast cancer groups and may impact treatment of women with this disease...
  6. pmc Tumoral lymphocytic infiltration and expression of the chemokine CXCL10 in breast cancers from the Ontario Familial Breast Cancer Registry
    Anna Marie Mulligan
    Keenan Research Centre, Li Ka Shing Knowledge Institute of St Michael s Hospital, University of Toronto, Ontario, Canada
    Clin Cancer Res 19:336-46. 2013
    ..Chemokines could play a role in attracting these cells and contribute to tumor progression. We explored tumoral expression of CXCL10 and determined the relationship between CXCL10 and lymphocytic infiltrate in a cohort of breast cancers...
  7. ncbi Changes in estrogen receptor, progesterone receptor and Her-2/neu status with time: discordance rates between primary and metastatic breast cancer
    Reuben J Broom
    Princess Margaret Hospital, Toronto, Canada
    Anticancer Res 29:1557-62. 2009
    ..Changes in the receptor profile between primary and metastatic breast cancer tissue have been suggested. The degree of hormone receptor discordance in archival paired pathological samples was evaluated...
  8. doi Cytokeratin 5 and estrogen receptor immunohistochemistry as a useful adjunct in identifying atypical papillary lesions on breast needle core biopsy
    Andrea Grin
    Department of Laboratory Medicine and Pathobiology, University of Toronto, Canada
    Am J Surg Pathol 33:1615-23. 2009
    ..Patterns and extent of ER and CK5 staining, when used together, are valuable adjunct stains to differentiate usual duct hyperplasia from atypical proliferations within papillary lesions on core biopsy...
  9. doi Müllerian adenosarcomas with unusual growth patterns: staging issues
    Blaise Alexander Clarke
    Department of Pathology, University Health Network, Toronto, Ontario, Canada
    Int J Gynecol Pathol 30:340-7. 2011
    ..This will facilitate reliable data collection such that an evidence-based staging system for these scenarios may be derived...
  10. doi Comparison of clinical schemas and morphologic features in predicting Lynch syndrome in mutation-positive patients with endometrial cancer encountered in the context of familial gastrointestinal cancer registries
    Paul Ryan
    Department of Pathology, Mount Sinai Hospital, Toronto, Ontario, Canada
    Cancer 118:681-8. 2012
    ..In this study, the authors determined the efficacy of family/personal history and tumor morphology in predicting LS in a cohort of patients with EC who had mutation-proven LS...
  11. doi Use of mismatch repair immunohistochemistry and microsatellite instability testing: exploring Canadian practices
    Steve E Kalloger
    Department of Pathology, University of British Columbia, Vancouver, BC, Canada
    Am J Surg Pathol 36:560-9. 2012
    ....
  12. doi The effect of prolonged fixation on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast cancer: a prospective study
    Leung Chu Tong
    Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
    Am J Surg Pathol 35:545-52. 2011
    ..In 6 of these, a higher score was seen in the PF group. In conclusion, fixation for limited periods beyond 72 hours does not result in a reduction in assay sensitivity in the determination of ER, PR, or HER2 immunohistochemical status...
  13. ncbi Endometrial giant cell carcinoma: a case series and review of the spectrum of endometrial neoplasms containing giant cells
    Anna Marie Mulligan
    Department of Laboratory Medicine, St Michaels Hospital, Toronto, ON, Canada
    Am J Surg Pathol 34:1132-8. 2010
    ..At this time, however, the cumulative data on endometrial GCC are limited and the prognostic significance of the presence and the extent of a giant cell component in endometrial carcinoma remains uncertain...
  14. ncbi High-level JAG1 mRNA and protein predict poor outcome in breast cancer
    Brendan C Dickson
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, Canada
    Mod Pathol 20:685-93. 2007
    ....
  15. doi Papillary lesions of the breast: impact of breast pathology subspecialization on core biopsy and excision diagnoses
    Kiran Jakate
    Department of Laboratory Medicine and Pathobiology, University of Toronto, ON, Canada
    Am J Surg Pathol 36:544-51. 2012
    ....
  16. ncbi PGDS, a novel technique combining chromogenic in situ hybridization and immunohistochemistry for the assessment of ErbB2 (HER2/neu) status in breast cancer
    Ruoyu Ni
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, Canada
    Appl Immunohistochem Mol Morphol 15:316-24. 2007
    ..It is likely that this assay will aid in immunohistochemical calibration and will also increase the sensitivity and specificity of ErbB2 testing...
  17. ncbi Metastatic potential of encapsulated (intracystic) papillary carcinoma of the breast: a report of 2 cases with axillary lymph node micrometastases
    Anna Marie Mulligan
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, and the University of Toronto, Toronto, Ontario, Canada
    Int J Surg Pathol 15:143-7. 2007
    ..The current 2 cases offer evidence to support the use of this term for particularly large encysted lesions. Sentinel lymph node biopsy may be prudent in such cases...
  18. ncbi Insulin receptor is an independent predictor of a favorable outcome in early stage breast cancer
    Anna Marie Mulligan
    Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, Canada
    Breast Cancer Res Treat 106:39-47. 2007
    ..Furthermore, high expression of IR is independently and significantly associated with more favorable clinical outcomes. Follow-up intervention research is recommended...